These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16815733)

  • 21. Biomedical imaging in the safety evaluation of new drugs.
    Wang YX; Yan SX
    Lab Anim; 2008 Oct; 42(4):433-41. PubMed ID: 18782821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The application of human embryonic stem cell technologies to drug discovery.
    Sartipy P; Björquist P; Strehl R; Hyllner J
    Drug Discov Today; 2007 Sep; 12(17-18):688-99. PubMed ID: 17826681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition.
    Giri S; Bader A
    Drug Discov Today; 2011 May; 16(9-10):382-97. PubMed ID: 21354326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An in vitro embryotoxicity assay based on the disturbance of the differentiation of murine embryonic stem cells into endothelial cells. II. Testing of compounds.
    Festag M; Viertel B; Steinberg P; Sehner C
    Toxicol In Vitro; 2007 Dec; 21(8):1631-40. PubMed ID: 17719739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro toxicology: a commercial proposition?
    Flint OP
    Xenobiotica; 1988 Jun; 18(6):707-14. PubMed ID: 3420946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methodology used in safety pharmacology: appraisal of the state-of-the-art, the regulatory issues and new directions.
    Pugsley MK
    J Pharmacol Toxicol Methods; 2005; 52(1):1-5. PubMed ID: 15982903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use and abuse of QT and TRIaD in cardiac safety research: importance of study design and conduct.
    Hondeghem LM
    Eur J Pharmacol; 2008 Apr; 584(1):1-9. PubMed ID: 18304526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential.
    Xu JJ; Diaz D; O'Brien PJ
    Chem Biol Interact; 2004 Nov; 150(1):115-28. PubMed ID: 15522265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relevance of in vitro SCREENIT results for drug-induced QT interval prolongation in vivo: a database review and analysis.
    Dumotier BM; Deurinck M; Yang Y; Traebert M; Suter W
    Pharmacol Ther; 2008 Aug; 119(2):152-9. PubMed ID: 18462801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune function tests for hazard identification: a paradigm shift in drug development.
    Gore ER
    Basic Clin Pharmacol Toxicol; 2006 Apr; 98(4):331-5. PubMed ID: 16623854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical safety evaluation of recombinant human interleukin-10.
    Rosenblum IY; Johnson RC; Schmahai TJ
    Regul Toxicol Pharmacol; 2002 Feb; 35(1):56-71. PubMed ID: 11846636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An integrated approach to improved toxicity prediction for the safety assessment during preclinical drug development using Hep G2 cells.
    Noor F; Niklas J; Müller-Vieira U; Heinzle E
    Toxicol Appl Pharmacol; 2009 Jun; 237(2):221-31. PubMed ID: 19332084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computational methods to predict drug safety liabilities.
    Durham SK; Pearl GM
    Curr Opin Drug Discov Devel; 2001 Jan; 4(1):110-5. PubMed ID: 11727316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability.
    Pugsley MK; Hancox JC; Curtis MJ
    Pharmacol Ther; 2008 Aug; 119(2):115-7. PubMed ID: 18590766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
    Hancox JC; McPate MJ; El Harchi A; Zhang YH
    Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do preclinical testing strategies help predict human hepatotoxic potentials?
    Peters TS
    Toxicol Pathol; 2005; 33(1):146-54. PubMed ID: 15805066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery.
    Neerman MF; Zhang W; Parrish AR; Simanek EE
    Int J Pharm; 2004 Aug; 281(1-2):129-32. PubMed ID: 15288350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.